HighTower Advisors’s Provention Bio PRVB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q1
– Sell
-25,820
Closed -$273K – 3737
2022
Q4
$273K Buy
25,820
+2,205
+9% +$17.8K ﹤0.01% 2544
2022
Q3
$106K Hold
23,615
– – ﹤0.01% 2755
2022
Q2
$95K Sell
23,615
-50
-0.2% -$237 ﹤0.01% 2797
2022
Q1
$174K Buy
+23,665
New +$142K ﹤0.01% 2875
2021
Q4
– Sell
-23,616
Closed -$151K – 3552
2021
Q3
$151K Buy
23,616
+900
+4% +$5.78K ﹤0.01% 2777
2021
Q2
$191K Buy
22,716
+6,416
+39% +$51.8K ﹤0.01% 2682
2021
Q1
$171K Buy
+16,300
New +$229K ﹤0.01% 2652
2018
Q4
– Sell
-35,047
Closed -$141K – 2409
2018
Q3
$141K Buy
+35,047
New +$139K ﹤0.01% 2010

Other funds holding PRVB

HighTower Advisors's PRVB Position: Q1 2023 in Review

HighTower Advisors sold out of Provention Bio (PRVB) in Q1 2023, closing a stake of 25,820 shares — an estimated $273K sold.

HighTower Advisors first reported a position in PRVB in Q3 2018 and held it in 8 quarters. The position peaked at $273K in Q4 2022. 182 funds tracked by Wall St. Rank hold PRVB as of Q1 2023.

  • HighTower Advisors reported no remaining Provention Bio position as of Q1 2023 after selling out during the quarter.
  • HighTower Advisors sold 25,820 Provention Bio shares in Q1 2023, an estimated $273K.
  • HighTower Advisors first reported a position in Provention Bio in Q3 2018 and held it in 8 quarters.
  • HighTower Advisors's Provention Bio position peaked at $273K in Q4 2022.
  • 182 funds tracked by Wall St. Rank held Provention Bio as of Q1 2023.

Based on HighTower Advisors's 13F filing for Q1 2023, filed 12 May 2023.